Accurate identification of snoRNA targets using variational graph autoencoder to advance the redevelopment of traditional medicines
Gespeichert in:
| Titel: | Accurate identification of snoRNA targets using variational graph autoencoder to advance the redevelopment of traditional medicines |
|---|---|
| Autoren: | Zhina Wang, Yangyuan Chen, Hongming Ma, Hong Gao, Yangbin Zhu, Hongwu Wang, Nan Zhang |
| Quelle: | Front Pharmacol Frontiers in Pharmacology, Vol 15 (2025) |
| Verlagsinformationen: | Frontiers Media SA, 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | Pharmacology, lung cancer, redevelopment of traditional medicines, variational graph autoencoder (VGAE), snoRNA therapeutic targets, Therapeutics. Pharmacology, RM1-950, artificial intelligence (AI) |
| Beschreibung: | Existing studies indicate that dysregulation or abnormal expression of small nucleolar RNA (snoRNA) is closely associated with various diseases, including lung cancer. Furthermore, these diseases often involve multiple targets, making the redevelopment of traditional medicines highly promising. Accurate prediction of potential snoRNA therapeutic targets is essential for early disease intervention and the redevelopment of traditional medicines. Additionally, researchers have developed artificial intelligence (AI)-based methods to screen and predict potential snoRNA therapeutic targets, thereby advancing traditional drug redevelopment. However, existing methods face challenges such as imbalanced datasets and the dominance of high-degree nodes in graph neural networks (GNNs), which compromise the accuracy of node representations. To address these challenges, we propose an AI model based on variational graph autoencoders (VGAEs) that integrates decoupling and Kolmogorov-Arnold Network (KAN) technologies. The model reconstructs snoRNA-disease graphs by learning snoRNA and disease representations, accurately identifying potential snoRNA therapeutic targets. By decoupling similarity from node degree, the model mitigates the dominance of high-degree nodes, enhances prediction accuracy in scenarios like lung cancer, and leverages KAN technology to improve adaptability and flexibility to new data. Case studies revealed that snoRNA SNORA21 and SNORD33 are abnormally expressed in lung cancer patients and are strong candidates for potential therapeutic targets. These findings validate the proposed model’s effectiveness in identifying therapeutic targets for diseases like lung cancer, supporting early screening and treatment, and advancing the redevelopment of traditional medicines. Data and experimental findings are archived in: https://github.com/shmildsj/data. |
| Publikationsart: | Article Other literature type |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2024.1529128 |
| Zugangs-URL: | https://doaj.org/article/c553efc486264dfca34df3bbee44c6bc |
| Rights: | CC BY |
| Dokumentencode: | edsair.doi.dedup.....b67e5ceb51a914f30cb09d86761ac656 |
| Datenbank: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Existing studies indicate that dysregulation or abnormal expression of small nucleolar RNA (snoRNA) is closely associated with various diseases, including lung cancer. Furthermore, these diseases often involve multiple targets, making the redevelopment of traditional medicines highly promising. Accurate prediction of potential snoRNA therapeutic targets is essential for early disease intervention and the redevelopment of traditional medicines. Additionally, researchers have developed artificial intelligence (AI)-based methods to screen and predict potential snoRNA therapeutic targets, thereby advancing traditional drug redevelopment. However, existing methods face challenges such as imbalanced datasets and the dominance of high-degree nodes in graph neural networks (GNNs), which compromise the accuracy of node representations. To address these challenges, we propose an AI model based on variational graph autoencoders (VGAEs) that integrates decoupling and Kolmogorov-Arnold Network (KAN) technologies. The model reconstructs snoRNA-disease graphs by learning snoRNA and disease representations, accurately identifying potential snoRNA therapeutic targets. By decoupling similarity from node degree, the model mitigates the dominance of high-degree nodes, enhances prediction accuracy in scenarios like lung cancer, and leverages KAN technology to improve adaptability and flexibility to new data. Case studies revealed that snoRNA SNORA21 and SNORD33 are abnormally expressed in lung cancer patients and are strong candidates for potential therapeutic targets. These findings validate the proposed model’s effectiveness in identifying therapeutic targets for diseases like lung cancer, supporting early screening and treatment, and advancing the redevelopment of traditional medicines. Data and experimental findings are archived in: https://github.com/shmildsj/data. |
|---|---|
| ISSN: | 16639812 |
| DOI: | 10.3389/fphar.2024.1529128 |